Melody valve registry tracks Long-Term outcomes in heart patients
NCT ID NCT06845371
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 845 people who previously received a Melody valve implant to treat congenital heart disease. Researchers will track serious events like death, repeat surgery, or infection over many years. The goal is to understand how well the valve performs long-term after it became commercially available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Melody valve
- What this could lead to
- If successful, this study could confirm the long-term safety and durability of the Melody valve in treating congenital heart disease.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL HEART DISEASE (CHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Tübingen
RECRUITINGTübingen, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could waiting longer to clamp the cord boost outcomes for babies with heart defects?
- AI reads heart scans to predict which children will develop serious complications
- Play therapy may calm young heart patients before surgery
- Stem cells given during infant heart surgery: a safety first
- Can a new guideline help mothers breastfeed babies with heart defects?
- Digital coach helps kids heal after heart surgery